Will Lixiana follow-ons take over the market?
By Moon, sung-ho | translator Kim, Jung-Ju
23.04.17 15:18:31
가나다라
0
Major domestic companies apply for approval of their generics... targets the NOAC market
Affected by KHRS’s guidelines... the impact of reimbursement to be in full swing this year
Activity in related markets has been rising due to the aftermath of the reimbursement approval for Transcatheter Aortic Valve Implantation (TAVI) that had been made last year.
Pharmaceutical companies have been increasingly conducting activities to target the Non-vitamin K antagonist oral anticoagulant (NOAC) market.
▲다이이찌산쿄 릭시아나 제품사진.
According to industry sources on the 17th, a series of marketing authorizations have been granted for follow-on drugs of Daiichi Sankyo’s NOAC drug ‘Lixiana (edoxaban)’ recently.More specifically, 6 incrementally modified drugs with different salt formations than the original, the 15mg and 30mg formulations of Hutecs Korea Pharmaceuticals’ ‘Enxiana,’ H
Moon, sung-ho(sjpark@medicaltimes.com)
If you want to see the full article, please JOIN US (click)